BIOCYTOGEN-B Shares Surge Over 6% in Afternoon Trading on Announcement of Major Project Investment

Stock News05-12 14:00

BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million.

The increase follows a recent company announcement that it plans to invest in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project, also known as the Nantong Haimen Phase IV Construction Project, through its wholly-owned subsidiary Jiangsu Biocytogen. The total investment for the project is approximately RMB 1.6 billion.

The project is aligned with the company's core business and aims to expand facility scale, increase production capacity, meet market demand, and enhance core competitiveness. Analysis from CITIC Securities points out that, alongside rapid business growth, the company's existing animal facilities are projected to reach full operational capacity by the end of 2025. A new 15,000-square-meter animal facility in Nantong Haimen, Jiangsu, is expected to be progressively operational by the third quarter of 2026, adding approximately 120,000 cage spaces.

Furthermore, the company has also planned for a new 90,000 to 100,000-square-meter animal facility in Nantong, slated for early 2026, to meet longer-term demand for innovative animal models and related CRO services.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143907967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143907967","market":"hk","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Surge Over 6% in Afternoon Trading on Announcement of Major Project Investment","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million.</p>\n<p>The increase follows a recent company announcement that it plans to invest in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project, also known as the Nantong Haimen Phase IV Construction Project, through its wholly-owned subsidiary Jiangsu Biocytogen. The total investment for the project is approximately RMB 1.6 billion.</p>\n<p>The project is aligned with the company's core business and aims to expand facility scale, increase production capacity, meet market demand, and enhance core competitiveness. Analysis from CITIC Securities points out that, alongside rapid business growth, the company's existing animal facilities are projected to reach full operational capacity by the end of 2025. A new 15,000-square-meter animal facility in Nantong Haimen, Jiangsu, is expected to be progressively operational by the third quarter of 2026, adding approximately 120,000 cage spaces.</p>\n<p>Furthermore, the company has also planned for a new 90,000 to 100,000-square-meter animal facility in Nantong, slated for early 2026, to meet longer-term demand for innovative animal models and related CRO services.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Surge Over 6% in Afternoon Trading on Announcement of Major Project Investment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Surge Over 6% in Afternoon Trading on Announcement of Major Project Investment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-12 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million.</p>\n<p>The increase follows a recent company announcement that it plans to invest in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project, also known as the Nantong Haimen Phase IV Construction Project, through its wholly-owned subsidiary Jiangsu Biocytogen. The total investment for the project is approximately RMB 1.6 billion.</p>\n<p>The project is aligned with the company's core business and aims to expand facility scale, increase production capacity, meet market demand, and enhance core competitiveness. Analysis from CITIC Securities points out that, alongside rapid business growth, the company's existing animal facilities are projected to reach full operational capacity by the end of 2025. A new 15,000-square-meter animal facility in Nantong Haimen, Jiangsu, is expected to be progressively operational by the third quarter of 2026, adding approximately 120,000 cage spaces.</p>\n<p>Furthermore, the company has also planned for a new 90,000 to 100,000-square-meter animal facility in Nantong, slated for early 2026, to meet longer-term demand for innovative animal models and related CRO services.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1143907967","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143907967","pubTimestamp":1778565628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million. The increase follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","02315":"百奥赛图-B","BK0216":"研究试验","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"宣布重大项目投资后，百奥赛图-B股午后交易飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"VXUS":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million.\nThe increase follows a recent company announcement that it plans to invest in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project, also known as the Nantong Haimen Phase IV Construction Project, through its wholly-owned subsidiary Jiangsu Biocytogen. The total investment for the project is approximately RMB 1.6 billion.\nThe project is aligned with the company's core business and aims to expand facility scale, increase production capacity, meet market demand, and enhance core competitiveness. Analysis from CITIC Securities points out that, alongside rapid business growth, the company's existing animal facilities are projected to reach full operational capacity by the end of 2025. A new 15,000-square-meter animal facility in Nantong Haimen, Jiangsu, is expected to be progressively operational by the third quarter of 2026, adding approximately 120,000 cage spaces.\nFurthermore, the company has also planned for a new 90,000 to 100,000-square-meter animal facility in Nantong, slated for early 2026, to meet longer-term demand for innovative animal models and related CRO services.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143907967","isCrawlerRequest":true}